Can a patient on hormone replacement therapy continue testosterone 50 mg injections, and what laboratory monitoring is required?

Testosterone 50mg Injections: Continuation and Monitoring Protocol

Yes, a patient can continue testosterone 50mg injections, as this dose falls within the standard therapeutic range for hormone replacement therapy (100-200mg every 2 weeks or 50mg weekly). 1, 2

Dosing Confirmation

The 50mg dose is appropriate and aligns with established guidelines:

• Standard dosing for testosterone enanthate/cypionate ranges from 50-400mg every 2-4 weeks, with 50mg weekly being a common regimen that minimizes fluctuations in serum levels 1, 2
• The FDA-approved dosing for testosterone cypionate specifically states "50 to 400mg should be administered every two to four weeks" for hypogonadal males 2
• Lower, more frequent dosing (50mg weekly) is preferred over higher, less frequent dosing because it reduces time spent in both supratherapeutic and subtherapeutic ranges, potentially lowering cardiovascular risk 1

Required Laboratory Monitoring

Baseline Testing (Before Starting or If Not Yet Done)

Prior to continuation, ensure the following baseline values are documented: 1

• PSA level (mandatory for men over 40 years) 1
• Hemoglobin/hematocrit 1
• Digital rectal examination 1
• Lipid panel (optional but recommended) 1
• Assessment for sleep apnea history 1
• Voiding symptoms evaluation 1

Ongoing Monitoring Schedule

Follow this time-dependent monitoring protocol: 1

First Follow-Up (1-2 Months After Initiation)

• Serum testosterone level (measured midway between injections, targeting 500-600 ng/dL) 1
• Assess symptomatic response and adverse effects 1
• Consider dose adjustment if testosterone levels suboptimal with inadequate clinical response 1

Subsequent Monitoring (3-6 Month Intervals for First Year)

• Serum testosterone level 1
• Hemoglobin/hematocrit 1
• PSA level 1
• Digital rectal examination 1
• Assessment of voiding symptoms 1
• Evaluation for sleep apnea symptoms 1

Annual Monitoring (After First Year)

• Continue yearly measurements of testosterone, hematocrit, and PSA 1
• Annual digital rectal examination 1
• Ongoing symptom assessment 1

Critical Safety Thresholds Requiring Intervention

Hematocrit Elevation (Most Common Adverse Effect with Injections)

Erythrocytosis occurs in 43.8% of patients receiving intramuscular testosterone injections (compared to only 15.4% with transdermal preparations) 1

Action thresholds: 1, 3

• Hematocrit >50% at baseline: Withhold therapy until etiology investigated 1
• Hematocrit >54% during treatment: Requires intervention including dose reduction, temporary discontinuation, therapeutic phlebotomy, or blood donation 1

PSA Elevation

Perform prostate biopsy if: 1

• PSA increases ≥1.0 ng/mL in any 12-month period 1
• PSA increases 0.7-0.9 ng/mL in one year: repeat PSA in 3-6 months and biopsy if any further increase 1

Absolute Contraindications to Continuation

Stop testosterone therapy immediately if any of the following develop: 1, 3, 4

• Breast or prostate cancer diagnosis 1, 3, 4
• PSA >4 ng/mL (or >3 ng/mL in high-risk patients) without urological evaluation 1, 3, 4
• Hematocrit >50% without investigation 1
• Severe untreated obstructive sleep apnea 1, 3, 4
• Uncontrolled heart failure 1, 3, 4
• Myocardial infarction or stroke within last 6 months 1, 3

Common Pitfalls and Caveats

Timing of Testosterone Measurement

For patients receiving injections, testosterone must be measured midway between injections to avoid misleading results from peak or trough levels 1. Peak levels occur shortly after injection and may be transiently supraphysiologic, while trough levels before the next dose may be subtherapeutic 1.

Cardiovascular Safety

While the 2015 FDA required labeling changes warning of possible cardiovascular risk 1, the recent TRAVERSE trial demonstrated no increased risk of major adverse cardiovascular events with testosterone therapy 5. The earlier concerns may have been related to high-risk patient populations and lack of appropriate comparator groups 1.

Fertility Considerations

Testosterone therapy suppresses gonadotropins (LH and FSH) in all treated patients, leading to testicular atrophy and severely compromised fertility 1, 6. Patients interested in future fertility should discontinue testosterone well in advance of conception attempts, though recovery time is highly variable 1.

Injection-Specific Risks

Intramuscular injections carry risks of local pain, soreness, bruising, erythema, swelling, nodules, or furuncles 1. Testosterone cypionate should never be given intravenously and must be administered deep in the gluteal muscle 2.